Reference

1. ^^абGanellin, C. R.; Triggle, D. J.; Macdonald, F. (1997).Dictionary of pharmacological agents. CRC Press. стр. 916.ISBN 978-0-412-46630-4. Приступљено15. 9. 2011. 
2. ^Fischer-Cornelssen, K. A. (1984). „Fluperlapine in 104 schizophrenic patients. Open multicenter trial”.Arzneimittel-Forschung.34 (1A): 125—130.PMID 6145428. 
3. ^Woggon, B.; Angst, J.; Bartels, M.; Heinrich, K.; Hippius, H.; Koukkou, M.; Krebs, E.; Küfferle, B.; Müller-Oerlinghausen, B. (1984). „Antipsychotic efficacy of fluperlapine. An open multicenter trial”.Neuropsychobiology.11 (2): 116—120.PMID 6148712. 
4. ^Dieterle, D.; Eben, E.; Einhäupl, K.; Hippius, H.; Klein, H.; Rüther, E.; Schmauß, M. (2008). „The Effect of Fluperlapine in Acute Psychotic Patients”.Pharmacopsychiatry.17 (2): 57—60.PMID 6728910.doi:10.1055/s-2007-1017408. 
5. ^Woggon, B.; Heinrich, K.; Küfferle, B.; Müller-Oerlinghausen, B.; Pöldinger, W.; Rüther, E.; Schied, H. W. (1984). „Results of a multicenter AMDP study with fluperlapine in schizophrenic patients”.Arzneimittel-Forschung.34 (1A): 122—124.PMID 6145427. 
6. ^Scholz, E.; Dichgans, J. (1985). „Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine”.European archives of psychiatry and neurological sciences.235 (1): 60—64.PMID 2864254. 
7. ^Pakkenberg, H.; Pedersen, B. (1985). „Medical treatment of dystonia”.Psychopharmacology. Supplementum.2: 111—117.ISSN 0179-8456.OCLC 10642795.PMID 2860654. 

Literatura

Vidi još

Spoljašnje veze